Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
{{output}}
Saxagliptin, a dipeptidyl peptidase-IV (DPP-IV) inhibitor, is currently under development by Bristol-Myers Squibb Co, AstraZeneca plc and Otsuka Pharmaceutical Co Ltd for the treatment of type 2 diabetes. The compound has high selectivity for DPP-IV compared w... ...
